# PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

> **NCT04787302** · PHASE1 · COMPLETED · sponsor: **Cerevel Therapeutics, LLC** · enrollment: 15 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** CVL-231
- **DRUG:** CVL-231
- **DRUG:** CVL-231

## Key facts

- **NCT ID:** NCT04787302
- **Lead sponsor:** Cerevel Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-01
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-07-14
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787302, "PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04787302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*